QSI

BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026.

BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.

BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument.

BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments.

BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing.

BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C.

Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

Quantum-Si NASDAQ: QSI said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cycle before production. The company also announced a targeted workforce reduction of about 20% as it seeks to lower cash burn and fund the revised development timeline.